Lab
Advanced Biomedical, INC.
Advanced Biomedical, INC. was paid $799K by Medicaid between Jan 2018 and Aug 2023, across 179 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 8.4% of everything it billed.
33Billing provider infoADVANCED BIOMEDICAL, INC.
SANTA ANA, CA 92704
SANTA ANA, CA 92704
33aNPI1518039486assigned 11/15/2006
33bProvider typeClinical Medical Laboratory
28Total paid$799K
24GClaims217,537
24DCodes billed179
24AFirst – last monthJan 2018 – Aug 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#204 of 561
Median peer was paid$222K
This provider vs. median3.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,158 | $44K | |
| 2019 | 1,598 | $7K | |
| 2020 | 24,489 | $320K | |
| 2021 | 67,845 | $276K | |
| 2022 | 64,059 | $64K | |
| 2023 | 56,388 | $88K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 8.4% | 3,548 | 2,147 | $67K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 5.6% | 4,546 | 3,338 | $44K |
| 81442 | 5.3% | 39 | 35 | $42K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.5% | 7,756 | 5,397 | $28K |
| 83970 | 3.4% | 1,049 | 949 | $27K | |
| 82172 | 3.0% | 821 | 788 | $24K | |
| 82670 | 2.9% | 1,180 | 1,070 | $23K | |
| 86769 | 2.8% | 616 | 593 | $23K | |
| 80426 | 2.8% | 227 | 203 | $23K | |
| 84403 | 2.3% | 1,031 | 955 | $18K | |
| 82627 | 2.1% | 1,087 | 980 | $17K | |
| 84270 | 2.1% | 1,051 | 973 | $17K |
167 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.0% | 2,806 | $16K |
| 84402 | 2.0% | 1,112 | $16K | |
| 84305 | 1.9% | 981 | $15K | |
| 84146 | 1.9% | 1,103 | $15K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.9% | 8,645 | $15K |
| 81414 | 1.9% | 40 | $15K | |
| 81413 | 1.8% | 38 | $14K | |
| 84481 | 1.8% | 1,786 | $14K | |
| 82607 | 1.8% | 5,115 | $14K | |
| 80061 | Lipid panel | 1.8% | 9,503 | $14K |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 1.7% | 9,356 | $13K |
| 83001 | 1.6% | 933 | $13K | |
| 82746 | 1.6% | 2,191 | $13K | |
| 82533 | 1.5% | 981 | $12K | |
| 86800 | 1.4% | 951 | $11K | |
| 83090 | 1.4% | 797 | $11K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.3% | 2,919 | $11K |
| 86376 | 1.3% | 959 | $10K | |
| 80053 | Comprehensive metabolic panel | 1.3% | 14,089 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.2% | 9,165 | $10K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 1,829 | $10K |
| 84144 | 1.2% | 651 | $9K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 14,995 | $9K |
| 81408 | 1.0% | 379 | $8K | |
| 84410 | <1% | 234 | $8K | |
| 84439 | <1% | 4,070 | $7K | |
| 86038 | <1% | 760 | $7K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,823 | $6K |
| 83550 | <1% | 1,624 | $6K | |
| 81286 | <1% | 39 | $6K | |
| 87481 | <1% | 3,207 | $5K | |
| 84153 | <1% | 962 | $5K | |
| 86803 | <1% | 406 | $5K | |
| 83735 | <1% | 1,890 | $4K | |
| 83540 | <1% | 2,082 | $4K | |
| 81439 | <1% | 122 | $4K | |
| 86704 | <1% | 387 | $4K | |
| 86317 | <1% | 285 | $4K | |
| 82728 | <1% | 1,144 | $4K | |
| 83002 | <1% | 240 | $3K | |
| 87340 | <1% | 329 | $3K | |
| 80074 | <1% | 249 | $3K | |
| 86140 | <1% | 859 | $3K | |
| 80050 | General health panel | <1% | 1,120 | $2K |
| 86431 | <1% | 591 | $2K | |
| 86780 | <1% | 218 | $2K | |
| 87653 | <1% | 3,369 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,685 | $2K |
| 87641 | <1% | 3,228 | $2K | |
| 82977 | <1% | 459 | $2K | |
| 87500 | <1% | 3,190 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 144 | $2K |
| 87556 | <1% | 2,156 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,805 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,742 | $2K |
| 82150 | <1% | 327 | $2K | |
| 87563 | <1% | 2,634 | $1K | |
| 87561 | <1% | 1,793 | $1K | |
| 87640 | <1% | 2,035 | $1K | |
| 84702 | <1% | 127 | $1K | |
| 84466 | <1% | 138 | $1K | |
| 84436 | <1% | 1,146 | $1K | |
| 87551 | <1% | 959 | $1K | |
| 86706 | <1% | 129 | $988.08 | |
| 83525 | <1% | 127 | $967.84 | |
| 84550 | <1% | 544 | $941.91 | |
| 86430 | <1% | 216 | $929.80 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 548 | $836.94 |
| 84479 | <1% | 744 | $834.09 | |
| 80164 | <1% | 1,301 | $770.19 | |
| 86592 | <1% | 653 | $767.17 | |
| 83880 | <1% | 750 | $710.56 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 29 | $704.64 |
| 83690 | <1% | 168 | $656.81 | |
| 86141 | <1% | 81 | $649.65 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,162 | $577.69 |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 7,857 | $469.25 |
| 85652 | <1% | 519 | $432.69 | |
| 86334 | <1% | 25 | $432.52 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 5,545 | $421.04 |
| 80051 | <1% | 143 | $411.57 | |
| 87529 | <1% | 643 | $401.40 | |
| 81001 | <1% | 2,827 | $399.56 | |
| 81404 | <1% | 1,156 | $390.99 | |
| 80177 | <1% | 443 | $374.61 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 72 | $366.77 |
| 82570 | <1% | 473 | $365.63 | |
| 85610 | <1% | 2,901 | $344.91 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,095 | $328.46 |
| 86708 | <1% | 25 | $282.21 | |
| 82140 | <1% | 175 | $269.63 | |
| 81003 | <1% | 1,349 | $250.95 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,006 | $238.75 |
| 83986 | <1% | 232 | $234.00 | |
| 84480 | <1% | 990 | $228.03 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 831 | $221.19 |
| 84134 | <1% | 350 | $185.96 | |
| 82550 | <1% | 242 | $167.98 | |
| 85027 | <1% | 1,474 | $167.92 | |
| 82947 | <1% | 131 | $164.99 | |
| 84545 | <1% | 25 | $156.86 | |
| 80076 | <1% | 277 | $136.07 | |
| 87511 | <1% | 577 | $100.19 | |
| 84460 | <1% | 44 | $99.80 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 666 | $96.52 |
| 84075 | <1% | 108 | $96.13 | |
| 84450 | <1% | 44 | $92.39 | |
| 82310 | <1% | 63 | $92.24 | |
| 82565 | <1% | 25 | $91.26 | |
| 82247 | <1% | 75 | $89.71 | |
| 82040 | <1% | 50 | $88.45 | |
| 87186 | <1% | 126 | $88.28 | |
| 84295 | <1% | 25 | $85.68 | |
| 84132 | <1% | 25 | $84.78 | |
| 84520 | <1% | 81 | $73.28 | |
| 82374 | <1% | 25 | $73.10 | |
| 82435 | <1% | 25 | $68.85 | |
| 87077 | <1% | 187 | $67.86 | |
| 87541 | <1% | 71 | $66.29 | |
| 87486 | <1% | 71 | $65.98 | |
| 84155 | <1% | 25 | $65.34 | |
| 87088 | <1% | 114 | $65.32 | |
| 87581 | <1% | 71 | $58.96 | |
| 82043 | <1% | 283 | $36.28 | |
| 82248 | <1% | 50 | $35.14 | |
| 83719 | <1% | 19 | $34.74 | |
| 80069 | <1% | 124 | $24.41 | |
| 87496 | <1% | 147 | $17.55 | |
| 84478 | <1% | 56 | $6.67 | |
| 84100 | <1% | 18 | $5.22 | |
| 82465 | <1% | 49 | $5.06 | |
| 85014 | <1% | 24 | $0.11 | |
| 85018 | <1% | 24 | $0.11 | |
| 81405 | 0% | 528 | $0.00 | |
| 87662 | 0% | 17 | $0.00 | |
| 83992 | 0% | 16 | $0.00 | |
| 81406 | 0% | 537 | $0.00 | |
| 80365 | 0% | 31 | $0.00 | |
| 86703 | 0% | 14 | $0.00 | |
| 80370 | 0% | 14 | $0.00 | |
| 81401 | 0% | 80 | $0.00 | |
| 81403 | 0% | 101 | $0.00 | |
| 80361 | 0% | 16 | $0.00 | |
| 80356 | 0% | 16 | $0.00 | |
| 80348 | 0% | 16 | $0.00 | |
| 81241 | 0% | 12 | $0.00 | |
| 81291 | 0% | 12 | $0.00 | |
| 80366 | 0% | 16 | $0.00 | |
| 80346 | 0% | 16 | $0.00 | |
| 80373 | 0% | 16 | $0.00 | |
| 80355 | 0% | 16 | $0.00 | |
| 80354 | 0% | 16 | $0.00 | |
| 80325 | 0% | 16 | $0.00 | |
| 87536 | 0% | 56 | $0.00 | |
| 87625 | 0% | 19 | $0.00 | |
| 80368 | 0% | 16 | $0.00 | |
| 81407 | 0% | 255 | $0.00 | |
| 87532 | 0% | 120 | $0.00 | |
| 80359 | 0% | 16 | $0.00 | |
| 81240 | 0% | 12 | $0.00 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 0% | 12 | $0.00 |
| 84703 | 0% | 12 | $0.00 | |
| 81161 | 0% | 39 | $0.00 | |
| 81226 | 0% | 12 | $0.00 | |
| 83615 | 0% | 22 | $0.00 | |
| 80358 | 0% | 16 | $0.00 | |
| 80178 | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSORRENTINO, JUDY (CFO)